Status:
TERMINATED
Efficacy and Safety Study of IBI-10090 in Cataract Surgery Patients
Lead Sponsor:
ICON Bioscience Inc
Conditions:
Ocular Inflammation
Eligibility:
All Genders
40+ years
Phase:
PHASE2
Brief Summary
This study will test the efficacy and safety of IBI-10090 in the treatment of ocular inflammation after cataract surgery.
Eligibility Criteria
Inclusion
- Male or female patients 40 years of age scheduled for unilateral cataract surgery (phacoemulsification or extracapsular extraction) with posterior chamber intraocular lens implantation.
Exclusion
- Patients who have used any ocular, topical, or oral corticosteroids within 7 days prior to Day 0.
- Patients who have used topical ocular NSAIDs in the study eye within 15 days prior to screening.
- Patients with any signs of intraocular inflammation in either eye at screening.
- Patients who have received any prior intravitreal injections in the study eye.
Key Trial Info
Start Date :
October 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2012
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT01214174
Start Date
October 1 2010
End Date
May 1 2012
Last Update
September 18 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Drs. Fine, Hoffman, and Packer
Eugene, Oregon, United States, 97401